Costello Medical Consulting Ltd 126-130 City House Cambridge CB2 1RE

United Kingdom

T +44 (0) 1223 913 020 www.costellomedical.com

Costello Medical ISPOR Presentations

ISPOR 20th Annual European Congress, November 2017, Glasgow, United Kingdom

IP9 Should Rare Oncology Treatments be Considered True Orphans? Griffiths A, Gajraj E, Pantziarka P, Cattaneo I

MD4 Evaluating Matching-Adjusted Indirect Comparison and Simulated Treatment Comparison Techniques: Impact on Health-Related Quality of Life of Focussed Ultrasound Thalamotomy and Other Interventions for the Treatment of Medication-Refractory Essential Tremor Langford BE, Ridley CJ, Beale RC, Marsh W, Caseby SC, Richard L

SY4 Do EU5 Countries with Favourable Healthcare Expenditure and Reimbursement Indicators have Better Patient Reported Access to Treatments for Rare Diseases? Allen G, Hall A, Hanman K, Le Fevre R, Griffiths A

PCN201 No EQ-5D? Analysis of Alternative Utility Value Sources used in NICE Appraisals for Oncology Indications Beale RC, Wickstead RM, Chen G, Walker E, Griffiths M

PHP3 Consumer Comments in Health Technology Assessment in Australia: How Common and Influential are They? Viswambaram A, McManus K, Miah R, Miles G

PHP60 Health Technology Assessment in Singapore: Shining a Light in the Darkness Viswambaram A, Brooks-Rooney C

PHP241 How do NICE Evidence Review Groups Perceive Single Technology Appraisals Presenting Limited Evidence of Comparative Treatment Efficacy? Langford BE, Beaver S, Besford M, Castell A, Dierker Viik A, Eddowes LA

PHP247 When the Price is Right: When, in Practice, are Confidential Discounts Introduced in the NICE Process? Noon K, Ulrich A, Painter C, Montgomery S

PHP262 An Audit of Evidence Review Group Criticisms of Systematic Literature Reviews Conducted to Inform Manufacturers’ Submissions to the National Institute for Health and Care Excellence Leonard S, Summers J, Young E

PHP300 Payers, Politics And Pandemonium: An Insight Into the Future UK Pricing and Market Access Environment Spoors J, Kusel J

PMD156 Does the NICE Diagnostics Assessment Programme Use an Empirical ICER Threshold? Chen G, Koczula KM, Peirce VJ, Marsh W

PRM118 Model Types Submitted to NICE: What is Considered Appropriate by Evidence Review Groups? Hearmon NC, Ghosh W, Buguth B, Kusel J

PRM242 An Exploration of the Methodology of Published Systematic Literature Reviews on “Burden of Disease” Buchanan-Hughes AM, Beaver S, Fell B, Summers J, Young E

PSY148 Why do ‘True’ Orphan Medicines Have Such a Low Acceptance Rate When Assessed by the SMC? Morten P, Ulrich A, Le Fevre R, Eddowes LA

ISPOR 22nd Annual International Meeting, May 2017, Boston, USA

PHP266 Value Frameworks to Set Tongues Wagging: Analysis of Opinions and Discussions on Key Value Frameworks Koczula K, Noon K, Wickstead R, Ghosh W, Uchea C, Kusel J

PHS131 Inequity in Healthcare Access in Asian Countries with Reportedly High Universal Health Coverage Levels Evans J, Ma C, Noon K, Steeves S

PMD74 Cost-Effectiveness of PET-CT Versus Adrenal Vein Sampling for the Diagnosis of Hypertension Caused by Primary Aldosteronism Lin Z, Kusel J, Ghosh W, Brown M

PMD118 Small and Medium-Sized Enterprises: How Do They Fare in the UK Medical Technologies Evaluation Programme (MTEP)? Ridley C, Marsh W

ISPOR 19th Annual European Congress, November 2016, Vienna, Austria

IP7 How Should Biosimilars be Valued and Should They Undergo Health Technology Assessment? Kusel J, Psachoulia E, McKenna F, Walker A

IP21 Is Off-Label Drug Use Enhancing or Limiting Access for Patients with Rare Diseases? Griffiths A, Scannell J, Timmis O, Pinilla-Dominguez P

PRM128 Pharmacological Interventions for Familial Hypercholesterolaemia in Children and Adolescents: An Exploratory Evaluation Using Advanced Hierarchical Network Meta-Analysis Techniques Langford B, Wickstead R, Murphy D, Marsh W, Beale R, Evans J, Kusel J, Griffiths M

PRM210 Adapting to the Challenge: How are Innovative Study Designs Being Used in Rare Diseases? Berry L, Eddowes L

PIN70 Health State Utility Values Measured Using the EuroQol 5-Dimensions Questionnaire in Adults with Chronic Hepatitis C: A Systematic Literature Review Buchanan-Hughes A, Hanman K, Langford B, Eddowes L

PHP6 Patient Group Submissions in Health Technology Assessment in Scotland: Prevalence and Impact Hamilton K, Hanman K, Griffiths M

PHP94 Do Scottish Formulary Decisions Match Recommendations Made by the SMC? Beale R, Kusel J

PCV16 Pharmacological Interventions for Familial Hypercholesterolaemia in Children and Adolescents: A Systematic Literature Review Wickstead R, Evans J, Langford B, Beale R, Marsh W, Kusel J, Griffiths M

PSY156 A Value for Money Threshold for New Technologies for Very Rare Conditions: Does the NICE Highly Specialised Technology Committee Employ One? Kusel J, Griffiths A, Spoors J

PCN236 Innovative Therapies for the Treatment of Cancer: An Overview of Late-Phase Clinical Development Resemann H, Chainani N, Morten P, Griffiths M

PCN294 Reconsidering Drugs Funded via the Cancer Drugs Fund in England: What’s New This Time? Morten P, Lin Z, Kusel J

PMD23 Cost of Ebola Virus Disease Diagnosis Using Rapid Point-of-Care Diagnostics in Sierra Leone Evans J, Hearmon N, Beale R, Marsh W

PMD59 Investigating the Cost-Effectiveness of Genetic Counselling for Couples at Known Risk of Having Children with Tay-Sachs Disease: A Two-Generation Model Ghosh W, Griffiths M, Griffiths A

ISPOR 7th Asia-Pacific Conference, September 2016, Singapore

IP3 Joint HTA: The Next Step for the ASEAN Economic Community? Chen G, Ngorsurachet S, Redekop K

IP15 Should Productivity Losses due to Illness be Considered in Health Economic Evaluations? Brooks-Rooney C, Redekop K, Wee HL, Milea D

PCV33 Measurement of Adherence to Anti-Hypertensive Drugs in Asia Ma Q, Kao C, Miles G, Chen G

PCV54 Quantifying Informal versus Formal Care, and Financial Caregiver Burden, for Stroke Patients in Asia: A Structured Literature Review Wayman S, Langford B, Buchanan-Hughes A, Chen G

PHP38 Universal Health Coverage in Countries across East and South East Asia – Associations between Health Expenditure and Service Provision Evans J, Wickstead R, Hanman K, Steeves S

PIN15 Economic Burden of Antibiotic-resistant Nosocomial Gram-Negative Bacteraemia in Singapore Hospitals Chen G, Lim S, Ma Q, Kao C, Ghosh W PMH16 Estimating the Economic Impact due to Productivity Losses of Diabetes and Major Depressive Disorder in Singapore: Human Capital versus Friction Cost Approaches Brooks-Rooney C, Griffiths M, Chen G

ISPOR 21st Annual International Meeting, May 2016, Washington DC, USA

PHP54 The Trade-Off Between QALY Maximisation and Social Values: A Systematic Review of Public Opinion Surveys Buchanan-Hughes A, Kusel J

ISPOR 18th Annual European Congress, November 2015, Milan, Italy

PCN323 Does Budget Impact Affect Reimbursement Decisions Made by the Cancer Drugs Fund in England? Stewart G, Kusel J, Montgomery S

PUK15 Investigating the Cost-Effectiveness of Bacterial Whole-Genome Sequencing for Enabling Targeted Antibiotic Selection in Urinary Tract Infections Buchanan-Hughes A, Griffiths A, Evans J, Slater D, Eddowes L

PDB116 The Role of Education in the Management of Type 1 Diabetes Mellitus in England Toth C, Marsh W, Stewart G, Yang L, Bridges H, Kusel J

PRM237 Using Incentives to Improve Health-Related Behaviours: A Review of Incentive-Based Trials Bunting C, Lim S, Morten P

PRM267 Development of a PRECIS-2 Scoring Grid: How Pragmatic are Pragmatic Trials of Surgical and Pharmaceutical Interventions? Chen G, Ma Q, Yang L, Ghosh W, Kusel J

PRM55 Hunting for Randomised Controlled Trials (RCTs): A Comparison of Search Filters Designed to Identify RCTs Steeves S, Buchanan-Hughes A, Evans J, Leonard S

ISPOR 5th Latin America Conference, September 2015, Santiago, Chile

IP2 Disinvestment in Latin America: What are the Experiences, Challenges and Proposals for its Successful Implementation? Agirrezabal I, Rodríguez A, Esandi ME, Gutiérrez-Ibarluzea I

PP4 An Undeveloped Picture: The Availability of Utility Valuations in Latin America. How Will They Affect QALYs? Montgomery S, Stewart G, Kusel JPHP23 Pharmaceutical Cost-Containment Strategies – Opinions of the Pharmaceutical Industry and HTA Bodies in Latin America Beale R, Stewart G, Agirrezabal I, Kusel J

PHP24 Immunisation in Latin America: Factors Preventing Uptake of Cost-Effective Vaccines Burgon J, Bunting C, Eddowes LA, Wilson T

PHP38 Considerations for the Adoption of the WHO-CHOICE Cost-Effectiveness Threshold in Latin America Griffiths M, Latchford J, Stewart G, Kusel J

PHP40 Clinical Trial Trends in Latin America: Communicable Versus Non-Communicable Disease Anderson R, Wilson T

PHP54 Disinvestment Initiatives in Latin America: A Systematic Literature Review Agirrezabal I, Latchford J, Gutierrez-Ibarluzea I

PRM9 A Systematic Review of Economic Evaluations in Latin America: Assessing the Factors That Affect Adaptation and Transferability of Results Stewart G, Slater D, Maruszczak M

ISPOR 20th Annual International Meeting, May 2015, Philadelphia, USA

PMD34 A System Dynamics Model for the Cost-effectiveness Evaluation of Bacterial Whole-genome Sequencing for Detecting and Monitoring Outbreaks of MRSA Agirrezabal I, Buchanan-Hughes A, Eddowes L, Luheshi L, Sagoo GS, Török ME

PMD37 A System Dynamics Model for the Cost-effectiveness Evaluation of Bacterial Whole-genome Sequencing for Monitoring Outbreaks of Clostridium difficile Buchanan-Hughes A, Agirrezabal I, Eddowes L, Luheshi L, Török ME, Sagoo GS

PRM28 Implication of the Inter-relatedness of the Proportional and Absolute QALY Shortfall Measurements for Disease Burden Kusel J, Beale R, Maruszczak M

PHP107 The WHO-Choice Cost-effectiveness Threshold: A Country-level Analysis of Changes Over Time Griffiths M, Maruszczak M, Kusel J

ISPOR 17th Annual European Congress, November 2014, Amsterdam, The Netherlands

W5 Value-based Assessment for NICE: How to Do the Calculations Kusel J, Boysen M, Hatswell AJ, Shah K

HS3 Impact of Morbidity in Populations of North London Clinical Commissioning Groups on Patient Admission Rates and GP Referrals Groom ZC, Burgon J, Eddowes LA, Wilson T, Kusel J

QA1 Economic Orphans? The Prevalence of Child-specific Utilities in NICE Appraisals for Paediatric Indications Montgomery S, Hassan M, Kusel J

NI2 Predicting the Impact of Value-based Assessment on Future NICE Appraisals Beale RC, Maruszczak M, Kusel J

PGI17 A Cost of Care Model for Inflammatory Bowel Disease with a UK NHS Perspective Miles G, Leonard SA, Ghosh N, Premchand P

PND49 Expected Value of Partial Perfect Information for the Disability Progression Efficacy of Teriflunomide and Fingolimod in the Treatment of Relapsing-remitting Multiple Sclerosis Maruszczak M, Kusel J, Adlard N

PMH63 Antidepressant Use and Suicide Rate in England: The Geographic Divide Anderson R, Wilson T, Griffiths M

PRM124 Discrete Event Simulation for the Cost-effectiveness Evaluation of PET-CT Scans in the Diagnosis of Conn’s Disease in Hypertensive Patients Maruszczak M, Stewart G, Kusel J, Brown MJ

PRM28 Systematic Review and Critique of Health Economic Models of Relapsing-remitting Multiple Sclerosis in the UK Kusel J, Maruszczak M, Montgomery S, Allen F, Adlard N

PCN260 Investigating the Use of Personalised Medicine in Cancer Trials – An Update Hamilton K, Wilson T

ISPOR 6th Asia-Pacific Conference, September 2014, Beijing, China

IP2 Disinvestment in Asia-Pacific: How Can This Be Implemented in HTA and What Can Be Learnt from Europe? Brooks-Rooney C, Kamae I, Tan ST, Gutiérrez-Ibarluzea I

QA2 An Analysis of New Health Technologies and Reimbursement Pricing Structure in Taiwan Stewart G, Brooks-Rooney C

PCN13 Analysing the Effects of a Disinvestment Decision in Breast Cancer Screening Programmes in Asia-Pacific Countries: A Modelling Approach Agirrezabal I, Bunting C, Brooks-Rooney C

PCN39 The Differences Between Cancer Drug Approvals in Japan and the USA Anderson R, Brooks-Rooney C

PDB9 Impact of Ethnicity on the Efficacy and Safety Outcomes of Anti-diabetes Drugs – Case Study of Liraglutide in Asian and Non-Asian Populations Chen G, Yang L, Lantaff B, Kusel J, Warnakula S, Brooks-Rooney C

PMS30 Closing the Gap: Reduced Delay to Drug Marketing Approval Between the West and Asia Hamilton KI, Eddowes LA, Brooks-Rooney C

PIN33 The Differences Between Infectious & Parasitic Drug Approvals in Japan and the USA Anderson R, Brooks-Rooney C

ISPOR 19th Annual International Meeting, May 2014, Montreal, Canada

HC2 The Impact of NICE’s End-Of-Life Threshold on the Availability of New Cancer Therapies in England and Wales Stewart G, Eddowes L, Hamerslag L, Kusel J

PHP27 An Update on How NICE Manage Off-Label Comparators Kusel J, Steeves S, Maruszczak M, Pettit L, Wilson T, Taylor D

PGI30 Patterns of Generic and Proprietary Prescribing of Proton Pump Inhibitors (PPIs) Over Time in England Hamilton K, Kusel J, Leonard S

PDB128 Insulin Pumps for the Treatment of Type 1 Diabetes Mellitus: Why is Uptake so Low in the UK? Marsh W, Wilson T, Kusel J

ISPOR 16th Annual European Congress, November 2013, Dublin, Ireland

IP13 Should Off-Label Agents Be Used as Comparators in Health Technology Assessments? Kusel J, Walker W, Spackman E, Andersson C

PCN207 Impact of Recommended Pharmaceuticals on Cancer Mortality: Analysis of Real-Life Data Wilson T, Hamerslag L, Kusel J

PHP152 The Relationship Between Scientific Research, Clinical Trials and FDA Drug Approval Burgon J, Hamerslag L

PHP166 How Does the Uncertainty Around the Expected ICER Affect NICE Decisions? Barber R, Steeves S, Wilson T, Hamerslag L, Kusel J

PMH68 How Well Do We Understand the Economic Burden Associated with Dementia? A Focus on Trends in Care Home Costs and Future Perspectives in the UK Griffiths M, Hamerslag L, Wilson T, Stewart G, Kusel J

PMS27 Global Variations in Biologics Access and Rheumatoid Arthritis Treatment Costs Miles G, Bell J, Wilson T, Hamerslag L, Kusel J

ISPOR 18th Annual International Meeting, May 2013, New Orleans, USA

PSY89 Treatment Options in Obesity: Is Clinical Development Keeping up with an Expanding Population? Hay J, Barber R, Kusel J, Wilson T

PMS48 Quality of Life in Rheumatoid Arthritis: How Much Do We Really Know? Miles GA, Rolfe F, Kusel J, Brooks-Rooney C, Hay J

PHP104 Assessing the Implementation of NICE Guidance: Is There a Correlation Between Recommendations and Uptake in Clinical Practice Pettit L, Leonard S , Brooks-Rooney C, Hamerslag L, Kusel J

ISPOR 15th Annual European Congress, November 2012, Berlin, Germany NI2 The Use of Off-Label Comparators in NICE Appraisals – An Indirect Endorsement? Kusel J, Wong GK, Hay JA, Pettit LJ

CA2 Applying a Value-Based Price Across Different Disease Areas Wilson TJ, Kusel J, Brooks-Rooney C, Costello S

PCN144 Access to Cancer Interventions Across the UK: To What Extent Does SMC Advice Agree with NICE’s End-of-Life Therapies? Hamerslag L, Brooks-Rooney C, Zhou A, Pettit L

ISPOR 5th Asia-Pacific Conference, September 2012, Taipei, Taiwan

HC4 Tapping into the Asian Pharmaceutical Market: Global Firms Go Local? Wong GKW, Brooks-Rooney C, Hamerslag L, Timm B, Wilson TJ, Costello S

PHP82 The Characteristics of Clinical Trials in Asia Brooks-Rooney C, Wong GKW, Hamerslag L, Costello S PRM11 The Use of Biomarkers in Cancer Trials in Asia Hamerslag L, Wilson T, Brooks-Rooney C

ISPOR 17th Annual International Meeting, June 2012, Washington DC, USA

PCN148 The Use of Personalised Medicine in Cancer Trials Wilson TJ, Hamerslag L, Kusel J, Brooks-Rooney C, Rolfe F, Costello S

PHP66 Assessing Agreement Between Patient Access Schemes: Review of NICE and SMC Guidance Timm B, Leonard S, Haynes S

PRM11 The Rise of Budget Impact Analyses – Another Hurdle in the Health Technology Approval Process? Wong GKW, Hamer N, Wilson T, Costello S

ISPOR 14th Annual European Congress, November 2011, Madrid, Spain

RS2 Cost-effectiveness of End-of-life, Life-extending Interventions: NICE’s Cost-effectiveness Threshold Explored Hamerslag L, Haynes S, Kusel J, Costello S

RS4 The Interim Cancer Drugs Fund – How To Not Spend £50 Million Timm B, Brooks-Rooney C, Hamerslag L, Costello S

PHP123 To What Extent Does Advice From the SMC Agree with that Published by NICE? Leonard SA, Brooks-Rooney C, Kusel J, Costello S

PHP145 The Burden of Evidence in the Pharmaceutical Appraisal Process Hamer N, Brooks-Rooney C, Timm B, Leonard S, Costello S

PHP152 The Administrative Burden of Patient Access Schemes in the Changing UK Healthcare System: A Follow Up Study Haynes S, Timm B, Hamerslag L, Wong G, Costello S

PRM9 What Guidance is Available for Budget Impact Analysis? Kusel J, Leonard S, Wilson T, Costello S

ISPOR 16th Annual International Meeting, May 2011, Baltimore, MD, USA

PRM3 The Burden of Caregiving: Assessing the Status of Current Clinical Research Hamer N, Costello S, Hamerslag L, Haynes S, Roper S

PHP5 Incentive-based Interventions – Rewarding Patients for Good Behaviour Haynes S, Costello S, Brooks-Rooney C, Hamer N

PHP7 Developing Public Health Guidance - What are the Data Gaps? Review of the Gaps in the Evidence Identified by NICE in the UK Kusel J, Hamer N, Roper S, Hamerslag L, Costello S

PHP43 The Influence of Patient Access Schemes on Appraisal Decisions by NICE in the UK Timm B, Kusel J, Hamer N, Brooks-Rooney C, Costello S

PHP89 The Implementation of Public Health Guidance: Preference for Clinical over Behavioural Interventions Hamerslag L, Kusel J, Haynes S, Brooks-Rooney C, Costello S

PMS69 The Use of Mixed Treatment Comparisons in NICE Technology Appraisals Brooks-Rooney C, Costello S, Kusel J, Timm B

ISPOR 13th Annual European Congress, November 2010, Prague, Czech Republic

NI4 Do Patient Access Schemes Result in an Acceptable Administrative Burden? Haynes S, Costello S, Brooks-Rooney C, Hamer N

PHP94 Is it Cost-Effective to Change the Behaviour of Healthcare Professionals? Kusel J, Costello S, Haynes S, Brooks-Rooney C, Hamer N, Timm B

PHP98 Cost-Effectiveness Methodologies of Strategies that Aim to Change the Behaviour of Healthcare Professionals Kusel J, Costello S, Haynes S, Brooks-Rooney C, Hamer N, Timm B

ISPOR 15th Annual International Meeting, May 2010, Atlanta, GA, USA

PHP79 Innovative Pricing Agreements in UK NICE Submissions Costello S, Haynes S, Kusel J, Brooks-Rooney C, Hamer N